Open Nav

Please submit your session questions in advance at

Oyster Point Pharma, Inc.

  • Jeffrey Nau, Oyster Point Pharma, Inc.

Oyster Point is a clinical-stage pharmaceutical company leveraging neuroscience to develop and commercialize novel therapies for ophthalmic diseases. The lead candidate has completed phase 2 and is an innovative therapeutic with the potential become the standard of care for Dry Eye Disease (DED) with $2B+ annual global revenue potential. DED affects over 30 million adults in the US and over 340 million people globally. The company’s leadership team has extensive experience developing and commercializing ophthalmology therapies at companies including Genentech, Allergan, OptiMedica, Oculeve, Ophthotech, Guidant, and Eyetech. Oyster Point was founded in 2015 by neuroscientist and entrepreneur Dr. Michael Ackermann, past CEO of Oculeve (acquired by Allergan). The company is preparing to initiate Phase 3 trials in 2019. The current investors are NEA and Versant Ventures. Oyster Point is headquartered in Princeton, NJ.

  • Date:Tuesday, February 12
  • Time:10:30 AM - 10:45 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23311
  • Goal for Presentation:Build awareness among investors of the innovation and value of Oyster Point Pharma
  • Company
  • Company HQ City:Princeton
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$28 Million
  • Size of Last Investment Round:$22 Million
  • Previous and Current Investors:NEA and Versant Ventures
  • CEO/Top Company Official:Jeffrey Nau, PHD
  • Year Founded:2015
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development:OC-01
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):1 - 4
  • Additional Information/Comments:Oyster Point would be a first time presenter at the conference. We anticipate seeking an additional round of financing in 2019 as well as the potential entry into the public market.
Jeffrey Nau
Oyster Point Pharma, Inc.